Six pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
This week, NuPathe Inc. (PATH) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
GW Pharmaceuticals PLC Sponsored ADR (GWPH) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
This week, Watson Pharmaceuticals (WPI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
The rating of Lipocine, Inc. (LPCN) moves up this week, rising from a C to a B. Lipocine is engaged in the development of pharmaceutical products in the areas of men’s and women’s health. For more information, get Portfolio Grader’s complete analysis of LPCN stock.
Cardiome Pharma (CRME) improves from a C to a B rating this week. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of CRME stock.
AbbVie, Inc. (ABBV) shows solid improvement this week. The company’s rating rises from a C to a B. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.